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Molecular defects responsible for β-thalassemias (thal) were investigated among 254 chromosomes from 127 transfusion-
dependent unrelated thalassemic patients from two provinces in Northern Iraq. Among fourteen identiﬁed mutations, the seven
most common found in 88.2% of the thal chromosomes were: IVS-II-1 (G → A), IVS-I-1 (G → A), codon 8 (−AA), codon 39
(G → T), codon 8/9 (+G), codon 44 (−C), and codon 5 (−CT). There were some notable diﬀerences in frequencies of various
mutations in comparison to other Eastern Mediterranean populations, as well as between the two provinces studied. The latter
illustrates the relative heterogeneity of the mutations distribution in Iraq, and the need to screen other areas of the country, to
ensure establishing an eﬀective prenatal program.
1.Introduction
β-thalassemias (thal) are inherited defects in the rate of
synthesis of β globin chains of hemoglobin, that are widely
distributed throughout the world, with considerable fre-
quencies in the Eastern Mediterranean countries, including
Iraq [1–3]. The two most northern provinces of Iraq are
Dohuk and Erbil which cover together an area of around
20000 square kilometers (Figure 1), bordering Iran and
Turkey, with a population of around 2.2 million of mostly
ethnic Kurds. Thalassemia major is an important problem in
thesetwoprovincesaswellasotherpartsofthecountry,with
more than 700 registered transfusion-dependent patients in
the only two thalassemia centers in the two provinces. The
huge burden imposed on the health authorities and on the
patients and their families mandates that a proper preventive
program is established in this region. The latter requires
establishingthemolecularbasisofthisdiseaseinthearea.An
earlier smaller paper has looked at the molecular basis of this
disease among carriers in one province [4], while the current
study was designed to look at its basis among transfusion
dependent thalassemics, with the aim of establishing an
integrated prenatal program covering these two provinces.
2.MaterialsandMethods
A total of 127 unrelated transfusion dependent β-thal
patients, registered at the Erbil (74 cases) and Dohuk (53
cases) thal care centers, northern Iraq, were recruited. The
patients were all ethnic Kurds, with ages ranging between
1 and 38 years (median age of 9 years). They included 71
males and 56 females. Informed consent was obtained from
all subjects, and the study was approved by the research
councils of colleges of Medicine, Hawler Medical University,
and Dohuk University, Iraq. A 5mL sample was aspirated
by venipuncture from each subject, anticoagulated in EDTA,
frozen and then at the appropriate time had its DNA
extracted by a chloroform-phenol-based method. The DNA
was ampliﬁed in a multiplex reaction mixture, followed2 Molecular Biology International
Table 1: The distribution of various β-thalassemia mutations among 254 chromosomes from Northern Iraqi provinces of Dohuk and Erbil.
Mutation
Total number of
chromosomes
(Erbil/Dohuk)
Number of Homozygotes
(Number with
consanguineous parents)
Number of
Heterozygotes Overall Frequency
IVSII.1 (G >A ) 73 (42/31) 24 (13) 25 28.7
IVSI.1 (G >A ) 45 (34/11) 10 (6) 25 17.7
Codon 8 (−AA) 23 (19/4) 8 (5) 7 9.1
Codon 8/9 (+G) 23 (15/8) 3 (2) 17 9.1
Codon 39 (C >T) 23 (7/16) 8 (5) 7 9.1
Codon 44 (−C) 21 (2/19) 7 (4) 7 8.3
Codon 5 (−CT) 16 (8/8) 3 (3) 10 6.3
IVSI.6 (T >C )6 ( 5 / 1 ) 0 6 2 . 4
IVSI.5 (G >C ) 6 (1/5) 1 (1) 4 2.4
IVSI.110 (G >A ) 3 (3/0) 1 (0) 1 1.2
Codon 36/37 (−T) 2 (2/0) 1 (1) 0 0.8
IVSII.745 (C >G )1 ( 1 / 0 ) 0 1 0 . 4
Codon 22 (−7bp) 1 (1/0) 0 1 0.4
Codon 30 (G >C )1 ( 0 / 1 ) 0 1 0 . 4
Uncharacterized 10 (8/2) 3 (3) 4 3.9
Total 254 (148/106) 69 (43) 116
by hybridization to speciﬁc wild and mutant oligoprobes
designed to detect 20 β-thal mutations which are encoun-
tered in Mediterranean countries (Vienna Labordiagnostica
GmbH, Vienna, Austria). The β-thal mutations screened for,
included: −87 (C→G); −30 (T→A); codon 5 (−CT); codon
6( −A); codon 8 (−AA); codon 8/9 (+G); codon 22 (−7bp);
codon 30 (G→C); IVS-I-1 (G→A); IVS-I-2 (T→A); IVS-
I-5 (G→C); IVS-I-6 (T→C); IVS-I-110 (G→A); IVS-I-116
(T→G); IVS-I (−25); codon 36/37(−T); codon 39 (C→T);
codon 44 (−C); IVS-II-1 (G→A); and IVS-II-745 (C→G).
The ampliﬁcation, hybridization, and detection procedures
were performed as recommended by the manufacturer.
3. Results
Among 254 β-thal chromosomes investigated, fourteen dif-
ferent mutations were identiﬁed. The seven most frequent
ones constituted 88.2% of all thal defects. These mutations
in order of frequency were IVS-II-1 (73 chromosomes:
28.7%), IVS-I-1 (45 chromosomes: 17.7%), codon 8 (−AA)
(23 chromosomes: 9.1%), codon 8/9 (23 chromosomes:
9.1%), codon 39 (23 chromosomes: 9.1%), codon 44 (21
chromosomes,8.3%),andcodon5(16chromosomes:6.3%).
Another seven mutations were less frequent or sporadic
including IVS-I-6, IVS-I-5, IVS-I-110, codon 36/37, codon
30, codon 22, and IVS-II-745 (Table 1). None of the studied
chromosomes had the −30 (T→A), −87 (C→G), IVS-I-2
(T→A), IVS-I-25 (25bp del), IVS-I-116 (T→G), or codon
6( −A) mutations. β-thal defects remained uncharacterized
in 10 chromosome (3.9%).
Among the 127 patients, 38 diﬀerent genotypes were
identiﬁed (Table 2). There were 69 homozygous patients,
while the rest were compound heterozygous. Forty three of
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Figure 1: Map of Iraq, showing Erbil and Dohuk provinces
(Shaded).
the 69 homozygous patients were the products of consan-
guineous marriages. The most frequent mutation among
homozygous patients was IVS-II-1 followed by IVS-I-1. The
most frequent compound heterozygous state was IVS-II-
1/IVS-I-1 followed by IVS-I-1/codon 8/9.
It was observed that while IVS-II-1 is the predominant
mutation in both provinces, there were notable diﬀerences
in distribution of other common mutants. Erbil province
contributed the larger proportion of IVS-I-1 (34/45), codon
8 (19/23) and codon 8/9 (15/23), while Dohuk contributedMolecular Biology International 3
Table 2: Beta-thalassemia genotypes among 127transfusion-
dependent thalassemic patients enrolled in the current study.
Genotype Number (%)
Homozygous
1I V S I I . 1 ( G >A )/IVSII.1 (G >A ) 24 (18.9)
2I V S I . 1 ( G >A )/IVSI.1 (G >A ) 10 (7.9)
3C o d o n 8 ( −AA)/Codon 8 (−AA) 8 (6.3)
4C o d o n 3 9 ( C >T)/Codon 39 (C >T)8 ( 6 . 3 )
5C o d o n 4 4 ( −C)/Codon 44 (−C) 7 (5.5)
6 Codon 8/9 (+G)/Codon 8/9 (+G) 3 (2.4)
7C o d o n 5 ( −CT)/Codon 5 (−CT) 3 (2.4)
8 IVSI-110 (G >A )/IVSI.110 (G >A )1 ( 0 . 8 )
9I V S I . 5 ( G >C )/IVSI.5 (G >C )1 ( 0 . 8 )
10 Codon 36/37 (−T)/Codon 36/37 (−T) 1 (0.8)
Compound Heterozygous
11 IVSII.1 (G >A )/IVSI.1 (G >A )9 ( 7 . 1 )
12 IVSI.1 (G >A )/Codon 8/9 (+G) 7 (5.5)
13 IVSI.1 (G >A )/IVSI.6 (T >C )3 ( 2 . 4 )
14 IVSII.1 (G >A )/Codon 8/9 (+G) 3 (2.4)
15 IVSII.1 (G >A )/Codon 8 (−AA) 3 (2.4)
16 Codon 8/9 (+G)/Codon 5 (−CT) 3 (2.4)
17 Codon 44 (−C)/codon 5 (−CT) 3 (2.4)
18 IVSI.1 (G >A )/Codon 8 (−AA) 2 (1.6)
19 IVSII.1 (G >A )/Codon 39 (C >T)2 ( 1 . 6 )
20 IVSII.1 (G >A )/Codon 5 (−CT) 2 (1.6)
21 Codon 39 (C >T)/codon 44 (−C) 2 (1.6)
22 IVSII.1 (G >A )/IVSI.6 (T >C )2 ( 1 . 6 )
23 IVS.I.5 (G >C )/codon 8/9 (+G) 2 (1.6)
24 IVSII.1 (G >A )/IVSI.110 (G >A )1 ( 0 . 8 )
25 Codon 5 (−CT)/Codon 8 (−AA) 1 (0.8)
26 IVSI.1 (G >A )/Codon 39 (C >T)1 ( 0 . 8 )
27 IVSII.1 (G >A )/IVSII.745 (C >G )1 ( 0 . 8 )
28 IVSI.1 (G >A )/codon 22 (−7bp) 1 (0.8)
29 IVSII.1 (G >A )/codon 30 (G >C )1 ( 0 . 8 )
30 IVSI.5 (G >C )/codon 8 (−AA) 1 (0.8)
31 IVSI.5 (G >C )/codon 44 (−C) 1 (0.8)
32 Codon 39 (C >T)/codon 5 (−CT) 1 (0.8)
33 Codon 39(C >T)/Codon 8/9 (+G) 1 (0.8)
34 Codon 44 (−C)/codon 8/9 (+G) 1 (0.8)
35 IVSI.1/Uncharacterized 2 (1.6)
36 IVS1.6/Uncharacterized 1 (0.8)
37 IVSII.1/Uncharacterized 1 (0.8)
38 Uncharacterized/Uncharacterized 3 (2.4)
Total 127 (100)
most cases of codon 44 (19/21) and codon 39 (16/23)
(Table 1).
4. Discussion
This study included transfusion dependent thal major
patients from two provincial thal centers covering a popu-
lation of more than two millions in northern Iraq. The latter
population includes mainly Ethnic Kurds, whose history
suggests that they have migrated to this region through
Iran more than 2500 years ago [5]. Thus, it would not be
unexpected that the IVS-II-1 mutation is the most frequent
mutation identiﬁed in our patients, since almost all Iranian
studies report the latter mutation as the most frequent
one, particularly those performed in Northwestern Iran and
among Iranian Kurds [6–8]. Such high rates of IVSII-1 are
not shared by Kurds of Diyarbakir in Southeastern Turkey
[9] or any other of Iraq neighboring states, except for eastern
Saudi Arabia and Kuwait [10, 11], which supports the notion
that latter rates may also be attributable to gene ﬂow from
neighboring Iran. The higher frequency of IVS-II-1 in Iran,
compared to its neighbors has led some investigators to
speculate that this mutation may have originated or have
undergone more eﬃcient selection there [6]. The other most
commonmutationsidentiﬁedinthecurrentstudy,wereIVS-
I-1 and codon 8, both Mediterranean β◦ mutations. The
frequenciesforbothlattermutationswereamongthehighest
reported in the eastern Mediterranean region [4, 6–15].
Moreover, the majority of chromosomes carrying the latter
two mutations were from Erbil, indicating further regional
variations even within the same ethnic group (Iraqi Kurds).
Codon 8/9 (+G) is an Asian Indian β◦ mutation, which is
common in the Indian subcontinent as well as Northwestern
Iran and in Iranian Kurds (14.5% and 15.7%, resp.) [7,
8]. This mutation is among the common mutation in the
current study and more so in Erbil nearer to Iran. Its
frequencyapparentlydecreasesaswemovewestandnorthto
Dohuk province and East Anatolia region of Turkey (5.1%)
[12]. The mutation is less common, sporadic, or absent in
other surrounding eastern Mediterranean countries [10–15].
Codon 8/9 presence in our region maybe related to trade
along the ancient Silk road which passed through this part
of northern Iraq.
Codon 39 is a Mediterranean β◦ mutation which is
common mainly in the Western Mediterranean, and its
frequency decreases as we move to the east except for high
frequencies in Saudi Arabia and Bahrain [15], and its high
frequencyamongourpatientsparticularlythosefromDohuk
is not quite expected, as it is not shared by the Kurds of
Southeastern Turkey or Western Iran at 2.8% and 1.7%,
respectively [8, 9]. Codon 5, on the other hand, which has
been considered a Kurdish/Iranian β◦ mutation was reported
in signiﬁcant proportion of cases in an earlier study from
Dohuk [4], as well as Iranian Kurds [8], but not from east
Anatolia region of Turkey [12].
It is interesting to note that codon 44, which has been
labeled as a Kurdish mutation [16], was only sporadically
reported in Erbil, and the majority of cases came from
Dohuk province. This is consistent with a study on Jewish
Kurds originating from Dohuk region and with an earlier
study on thal carriers from Dohuk which reported it as
the second most frequent mutation [4, 16]. This further
emphasizes the regional variation in mutation distribution
among Kurds and supports the notion that the latter
mutation maybe of recent origin, originating in the Dohuk
region, probably in the last 2000+ years, following the
Kurdish settlement in the region. Another Kurdish mutation,4 Molecular Biology International
codon 36/37 reported among the Lurs of western Iran as
well as Jewish and Iranian Kurds [8, 16, 17], was found
in homozygous state in only one patient from Erbil in
the current study, but not from Dohuk. Similarly, this
mutationwasonlysporadicinEastAnatoliaregionofTurkey
bordering the two Iraqi provinces [12].
Another important observation is that in contrast to
many other Eastern Mediterranean populations, where the
IVS-I-110 is the predominant mutation [9, 12–15], it was
only seen in 2.1% of our cases, a ﬁgure which is much lower
than the 27.8%, 18% and 6% reported, respectively, from
southeastern Turkey, northwestern and Kurdish Iranians [7–
9]. This mutation has its highest frequencies in Cyprus, but
its frequency gradually decreases in countries further to the
east, with a distribution pattern almost opposite to that of
IVS-II-1 [10, 11, 14, 15, 18].
It maybe argued that the high consanguinity rate among
homozygous individuals may have aﬀected the actual fre-
quencies of some of the mutations in the current study,
however, even if this is taken into account, the most frequent
seven mutations will remain so, and will not thus aﬀect the
overall prenatal diagnostic program in the region.
This study on Iraqi Kurds from northern Iraq, revealed
some similarities to studies from Iranian Kurds living across
the border in Iran, which consistent with the common origin
of these populations. However some notable diﬀerence in
the frequencies of some particular mutations between these
two population and within the Iraqi Kurds are likely to be
due either to recent origin of such mutations or to various
selective advantages (such as Malaria) which may have had
diﬀerent impacts on the rates observed. Such observations
further stress the need to screen other areas and ethnic
groups in the country, to ensure establishing an eﬀective
prenatal diagnostic program.
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